If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Health Canada Approves Budesonide/Formoterol Dry Powder Inhaler for COPD NEW YORK -- January 14, 2010 -- Health Canada Health Canada has approved budesonide/formoterol (Symbicort Turbuhaler), a dry powder inhaler, for the maintenance treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema. COPD is a chronic lung disease that progressively damages the airways that go in and out of the lungs. The use of budesonide/formoterol in the treatment of patients with moderate to severe COPD is supported by two 12-month, randomised, double-blind, placebo-controlled, parallel-group, multicentre studies comparing efficacy and safety of budesonide plus formoterol with budesonide montherapy, formoterol monotherapy or placebo. Budesonide/formoterol was shown to be effective in reducing exacerbations and providing early and sustained improvements in lung function and symptoms, together with improvements in health-related quality of life. “The Health Canada approval is exciting news for Canadians living with COPD, especially as [budesonide/formoterol] has been seen to provide patients with an increased quality of life and a reduction in exacerbations,” said Meyer Balter, MD, Asthma and COPD Education Clinic, Mount Sinai Hospital, Toronto, Ontario. “In addition, clinical trials have shown it to have a fast onset of action and ease the morning symptoms of COPD, giving patients a better start to their day, enabling them to live a more active life.”
SOURCE: Edelman Group
|
